Skip to main content
SpringerLink
Log in

Review of venous thromboembolism and race: the generalizability of treatment guidelines for high-risk populations

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

The American College of Chest Physicians (ACCP) has established guidelines for the treatment of VTE, but the generalizability to all populations is unclear. In this review we analyzed the rate of reporting and enrollment of blacks and women in clinical trials cited in the ACCP guidelines for treatment of unprovoked VTE. We extracted data from clinical trials cited by the ACCP that compared durations of anticoagulation therapy for the treatment of unprovoked VTE. We excluded trials that treated surgical or cancer patients. For trials that did not report race/ethnicity we contacted the primary investigators via email for enrollment data. The final analysis included 17 randomized clinical trials with a total patient population of N = 13,693. All trials reported data on sex; conversely, 2 trials (11.8 %) reported race/ethnicity within the primary manuscript. We ultimately acquired data on race/ethnicity from the primary investigator in 5 additional trials for a total race/ethnicity data from 7 trials. There were 7573 males (55.3 %) and 6120 females (44.7 %) enrolled in these studies. Among trials that reported race and ethnicity the total patient population was N = 5368; 5171 (96.3 %) white, 115 (2.1 %) black, 65 (1.4 %) Asian and 7 (0.25 %) Hispanic. Racial/ethnic minorities are underreported and under represented in clinical trials forming the cornerstone of ACCP guidelines for the optimal duration for VTE treatment. Conversely, the reporting and inclusion of women was substantive. The guidelines for unprovoked VTE treatment may not be generalizable to racially and ethnically diverse patient populations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rosendaal FR, Raskob GE (2014) On world thrombosis day. Lancet 384(9955):1653–1654

    Article  Google Scholar 

  2. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J (2007) Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 5(4):692–699

    Article  CAS  PubMed  Google Scholar 

  3. Beckman MG, Hooper WC, Critchley SE, Ortel TL (2010) Venous thromboembolism: a public health concern. Am J Prev Med 38(4):S495–S501

    Article  PubMed  Google Scholar 

  4. Zakai NA, McClure LA (2011) Racial differences in venous thromboembolism. J Thromb Haemost 9(10):1877–1882

    Article  CAS  PubMed  Google Scholar 

  5. White RH, Zhou H, Murin S, Harvey D (2005) Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost 93(2):298–305

    CAS  PubMed  Google Scholar 

  6. White RH, Keenan CR (2009) Effects of race and ethnicity on the incidence of venous thromboembolism. Thromb Res 123:S11–S17

    Article  CAS  PubMed  Google Scholar 

  7. Buckner TW, Key NS (2012) Venous thrombosis in blacks. Circulation 125(6):837–839

    Article  PubMed  Google Scholar 

  8. Aujesky D, Long JA, Fine MJ, Ibrahim SA (2007) African American race was associated with an increased risk of complications following venous thromboembolism. J Clin Epidemiol 60(4):410–416

    Article  PubMed  Google Scholar 

  9. Deitelzweig SB, Lin J, Johnson BH, Schulman KL (2011) Venous thromboembolism in the US: does race matter? J Thromb Thrombolysis 31(2):133–138

    Article  PubMed  Google Scholar 

  10. White RH, Dager WE, Zhou H, Murin S (2006) Racial and gender differences in the incidence of recurrent venous thromboembolism. Thromb Haemost-Stuttg 96(3):267

    CAS  Google Scholar 

  11. Liu J, Hickson DA, Musani SK, Talegawkar SA, Carithers TC, Tucker KL, Taylor HA (2013) Dietary patterns, abdominal visceral adipose tissue, and cardiometabolic risk factors in African Americans: the Jackson heart study. Obesity 21(3):644–651

    Article  PubMed  PubMed Central  Google Scholar 

  12. Austin H, Key NS, Benson JM, Lally C, Dowling NF, Whitsett C, Hooper WC (2007) Sickle cell trait and the risk of venous thromboembolism among blacks. Blood 110(3):908–912

    Article  CAS  PubMed  Google Scholar 

  13. Payne AB, Miller CH, Hooper WC, Lally C, Austin HD (2014) High factor VIII, von Willebrand factor, and fibrinogen levels and risk of venous thromboembolism in blacks and whites. Risk 24(2):169–174

    Google Scholar 

  14. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Kahn SR (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest J 141(2_suppl):e419S–e494S

    Article  CAS  Google Scholar 

  15. Lagerstedt C, Fagher B, Olsson CG, Öqvist B, Albrechtsson U (1985) Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 326(8454):515–518

    Article  Google Scholar 

  16. Research Committee of the British Thoracic Society (1992) Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 340(8824):873–876

    Google Scholar 

  17. Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg J, Powers P (1995) Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 74(2):606–611

    CAS  PubMed  Google Scholar 

  18. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Lärfars G, Nicol P, Boberg J (1995) A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 332(25):1661–1665

    Article  CAS  PubMed  Google Scholar 

  19. Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, Boberg J (1997) The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 336(6):393–398

    Article  CAS  PubMed  Google Scholar 

  20. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Julian JA (1999) A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340(12):901–907

    Article  CAS  PubMed  Google Scholar 

  21. Pinede L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S, Durieu I, Boissel J (2001) Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 103(20):2453–2460

    Article  CAS  PubMed  Google Scholar 

  22. Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Ageno W (2001) Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 345(3):165–169

    Article  CAS  PubMed  Google Scholar 

  23. Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Glynn RJ (2003) Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 348(15):1425–1434

    Article  CAS  PubMed  Google Scholar 

  24. Agnelli G, Prandoni P, Becattini C, Silingardi M, Taliani MR, Miccio M, Zonzin P (2003) Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 139(1):19–25

    Article  CAS  PubMed  Google Scholar 

  25. Farraj RS (2004) Anticoagulation period in idiopathic venous thromboembolism. How long is enough? Saudi Med J 25(7):848–851

    PubMed  Google Scholar 

  26. Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, Tripodi A (2006) D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 355(17):1780–1789

    Article  CAS  PubMed  Google Scholar 

  27. Campbell IA, Bentley DP, Prescott RJ, Routledge PA, Shetty HGM, Williamson IJ (2007) Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ 334(7595):674

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Siragusa S, Malato A, Anastasio R, Cigna V, Milio G, Amato C, Mariani G (2008) Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the duration of anticoagulation based on compression ultrasonography (DACUS) study. Blood 112(3):511–515

    Article  CAS  PubMed  Google Scholar 

  29. Prandoni P, Prins MH, Lensing AW, Ghirarduzzi A, Ageno W, Imberti D, Agnelli G (2009) Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med 150(9):577–585

    Article  PubMed  Google Scholar 

  30. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Goldhaber SZ (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361(24):2342–2352

    Article  CAS  PubMed  Google Scholar 

  31. Agnelli G, Berkowitz S, Bounameaux H, Büller H, Cohen A, Gallus A, Spadari G (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499–2510

    Article  PubMed  Google Scholar 

  32. Zhang T, Tsang W, Wijeysundera HC, Ko DT (2013) Reporting and representation of ethnic minorities in cardiovascular trials: a systematic review. Am Heart J 166(1):52–57

    Article  CAS  PubMed  Google Scholar 

  33. Jackson LR II, Peterson ED, Okeagu E, Thomas K (2015) Review of race/ethnicity in non vitamin K antagonist oral anticoagulants clinical trials. J Thromb Thrombolysis 39(2):222–227

    Article  CAS  PubMed  Google Scholar 

  34. REGULATION (EU) No 536/2014 of the European Parliament And of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC

  35. Sheikh A, Netuveli G, Kai J, Panesar SS (2004) Comparison of reporting of ethnicity in US and European randomised controlled trials. BMJ 329(7457):87–88

    Article  PubMed  PubMed Central  Google Scholar 

  36. Tsang W, Alter DA, Wijeysundera HC, Zhang T, Ko DT (2012) The impact of cardiovascular disease prevalence on women’s enrollment in landmark randomized cardiovascular trials: a systematic review. J Gen Intern Med 27(1):93–98

    Article  PubMed  Google Scholar 

  37. Sardar MR, Badri M, Prince CT, Seltzer J, Kowey PR (2014) Underrepresentation of women, elderly patients, and racial minorities in the randomized trials used for cardiovascular guidelines. JAMA Internal Med 174(11):1868–1870

    Article  Google Scholar 

  38. Ford ME, Siminoff LA, Pickelsimer E, Mainous AG, Smith DW, Diaz VA, Tilley BC (2013) Unequal burden of disease, unequal participation in clinical trials: solutions from African American and Latino community members. Health & social work. hlt001

Download references

Author information

Authors and Affiliations

  1. Duke Clinical Research Institute, Duke University Department of Medicine, 2400 Pratt Street, Durham, NC, 27705, USA

    Lonnie T. Sullivan II, Larry R. Jackson II & Kevin L. Thomas

Authors
  1. Lonnie T. Sullivan II
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Larry R. Jackson II
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kevin L. Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kevin L. Thomas.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sullivan, L.T., Jackson, L.R. & Thomas, K.L. Review of venous thromboembolism and race: the generalizability of treatment guidelines for high-risk populations. J Thromb Thrombolysis 42, 167–171 (2016). https://doi.org/10.1007/s11239-016-1352-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-016-1352-5

Keywords

Search

Navigation